Clinical features and genetic frequencies of Kozak ANV −1 C/T polymorphism, among patients and controls
| . | Control . | SIH . | DVT . | CHD . | MI before 45 y . |
|---|---|---|---|---|---|
| No. | 580 | 225 | 151 | 101 | 166 |
| Age, mean ± SD | 49.5 ± 19.6 | 67.4 ± 13.1* | 55.8 ± 17.7* | 62.9 ± 11.1* | 39.9 ± 4.6* |
| Sex, % males | 61.0 | 58.7 | 55.6 | 73.3* | 92.7* |
| Hypertension, % | 22.2 | 59.6* | — | 49.5* | 29.5 |
| Type I or II diabetes, % | 10.2 | — | — | 37.6* | 10.8 |
| Hypercholesterolemia, % | 12.6 | — | — | 42.6* | 78.9* |
| Smoking, % | 37.9 | 27.4* | — | 51.5* | 85.5* |
| Factor V Leiden +/−, % | 4.1 | — | 10.6* | — | — |
| Factor II 20210 A/G, % | 2.1 | — | 6.0* | — | — |
| Genotype | |||||
| −1 C/C, % | 446 (76.9) | 179 (79.6) | 123 (81.5) | 84 (83.2) | 144 (86.8) |
| −1 C/T + T/T, % | 128 + 6 (22.1 + 1.0) | 39 + 7 (17.3 + 3.1) | 28 + 0 (18.5 + 0) | 17 + 0 (16.8 + 0) | 20 + 2 (12.0 + 1.2) |
| P† | NA | .416 | .229 | .161 | .006 |
| OR (95% CI) | NA | 0.86 (0.58-1.27) | 0.76 (0.47-1.22) | 0.67 (0.37-1.21) | 0.51 (0.30-0.85) |
| Allele | |||||
| C | 0.879 | 0.882 | 0.907 | 0.916 | 0.928 |
| T | 0.121 | 0.118 | 0.093 | 0.084 | 0.072 |
| P† | NA | .872 | .175 | .134 | .013 |
| OR (95% CI) | NA | 0.97 (0.68-1.38) | 0.74 (0.47-1.16) | 0.67 (0.38-1.16) | 0.57 (0.35-0.91) |
| . | Control . | SIH . | DVT . | CHD . | MI before 45 y . |
|---|---|---|---|---|---|
| No. | 580 | 225 | 151 | 101 | 166 |
| Age, mean ± SD | 49.5 ± 19.6 | 67.4 ± 13.1* | 55.8 ± 17.7* | 62.9 ± 11.1* | 39.9 ± 4.6* |
| Sex, % males | 61.0 | 58.7 | 55.6 | 73.3* | 92.7* |
| Hypertension, % | 22.2 | 59.6* | — | 49.5* | 29.5 |
| Type I or II diabetes, % | 10.2 | — | — | 37.6* | 10.8 |
| Hypercholesterolemia, % | 12.6 | — | — | 42.6* | 78.9* |
| Smoking, % | 37.9 | 27.4* | — | 51.5* | 85.5* |
| Factor V Leiden +/−, % | 4.1 | — | 10.6* | — | — |
| Factor II 20210 A/G, % | 2.1 | — | 6.0* | — | — |
| Genotype | |||||
| −1 C/C, % | 446 (76.9) | 179 (79.6) | 123 (81.5) | 84 (83.2) | 144 (86.8) |
| −1 C/T + T/T, % | 128 + 6 (22.1 + 1.0) | 39 + 7 (17.3 + 3.1) | 28 + 0 (18.5 + 0) | 17 + 0 (16.8 + 0) | 20 + 2 (12.0 + 1.2) |
| P† | NA | .416 | .229 | .161 | .006 |
| OR (95% CI) | NA | 0.86 (0.58-1.27) | 0.76 (0.47-1.22) | 0.67 (0.37-1.21) | 0.51 (0.30-0.85) |
| Allele | |||||
| C | 0.879 | 0.882 | 0.907 | 0.916 | 0.928 |
| T | 0.121 | 0.118 | 0.093 | 0.084 | 0.072 |
| P† | NA | .872 | .175 | .134 | .013 |
| OR (95% CI) | NA | 0.97 (0.68-1.38) | 0.74 (0.47-1.16) | 0.67 (0.38-1.16) | 0.57 (0.35-0.91) |
Hypertension was defined as blood pressure exceeding 140 mm Hg (systolic) or exceeding 90 mm Hg (diastolic) on repeated observations during 3 months or, if no blood pressure values were available, by treatment for chronic antihypertensive therapy. Subjects were classified as “smoking” if they currently/formerly smoked more than 10 cigarettes per day. Hypercholesterolemia was defined as a total serum cholesterol level exceeding 5.72 mM (220 mg/dL).
SIH indicates spontaneous intracranial haemorrhage; DVT, deep venous thrombosis; CHD, coronary heart disease; MI, myocardial infarction; OR, odds ratio; CI, confidence interval, and NA, not applicable.
P < .05 between patients and controls.
Statistical comparison was performed between patients and controls.